This is a 24-week open trial. We will enroll long-COVID patients with cognitiveimpairments. All patients will receive DAOIB for 24 weeks. We will assess the patientsevery 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize thatDAOIB treatment will be beneficial in improving the cognitive function, mood symptoms,global functioning and quality of life in long-COVID patients with cognitive impairments.
Not Provided
Drug: DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Inclusion Criteria:
- "post-COVID-19 condition" defined by WHO (symptoms present at three months after
SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an
alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced
cognitive impairments
- physically healthy and have all laboratory assessments (including urine/blood
routine, biochemical tests, and electrocardiograph) within normal limits
- have sufficient education to communicate effectively and are capable of completing
the assessments of the study
Exclusion Criteria:
- history of significant cerebrovascular disease
- Hachinski Ischemic Score > 4
- major neurological, psychiatric or medical conditions other than long COVID-induced
cognitive impairments
- memantine use (memantine is an NMDAR partial antagonist)
- substance (including alcohol) abuse or dependence
- delusion, hallucination or delirium symptoms
- severe visual or hearing loss
- inability to follow the protocol
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan
Investigator: Chieh-Hsin Lin, MD, PhD
Contact: 886-7-7317123
cyndi36@gmail.com
Investigator: Chieh-Hsin Lin, MD, PhD
Not Provided